Arrowhead says ARO — MAPT cuts CSF total tau up to 73% in interim Phase 1/2a healthy — volunteer data
Arrowhead Pharmaceuticals released interim Phase 1/2a data for ARO-MAPT, an investigational RNAi drug targeting tau-related neurodegenerative diseases. Results were already presented as interim findings, with additional data scheduled for a company webinar later today. Healthy-volunteer dosing produced deep, sustained